Envue Medical Q2 FY26 net loss widens 23% to $4.9 million; revenue falls 51.6% to $239,000
Reuters2026/08/17 21:01- Envue Medical posted a net loss of USD 4.9 million for the quarter ended June 30, 2026, widening 23%.
- Revenue fell 51.6% to USD 239, due to a PainShield/UroShield production halt tied to the war in Israel.
- Gross loss widened to USD 266, on USD 140 of ENvue-merger amortization, discounted ENvue system sales, and a USD 41 inventory write-down.
- Selling and marketing expenses climbed 78% to USD 1.2 million, driven by ENvue commercialization and UroShield expansion into the U.K.
- Cash and cash equivalents totaled USD 1.08 million; management flagged substantial doubt about going concern over the next 12 months.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Delta Electronics (Thailand)'s Recent Selloff Presents Accumulation Opportunity -- Market Talk
The data center construction boom may increase inflationary pressure, and the Reserve Bank of Australia may be forced to maintain high interest rates.
The data center construction boom in Australia may lead to demand exceeding the supply capacity of the economy, which could push up inflation and force the Reserve Bank of Australia to maintain higher interest rates.
Reliance step-down unit Roptonal dissolves in Cyprus with effect Aug. 18, 2026
Crypto prices
More
